Cannabis is a Schedule 1 Controlled Substance under the Controlled Substance Act (21 U.S.C. 802) (“CSA”) and the cultivation, distribution, and possession of cannabis is a crime under federal law. The CSA and other Federal Statutes specifically prohibit persons from possessing, transferring, delivering, or cultivating cannabis within the territorial borders of the United States. The penalties for violation of these laws can be severe and may include incarceration. The United States Supreme Court has held that the Federal Government may still criminalize the production and use of cannabis regardless of whether a particular state within the United States has allowed for possession or use under certain circumstances, including use for medical purposes. See, Gonzalez v. Raich1.
This report, which offers health, wellness and cannabis information, is designed for use with the guidance of your medical practitioner and is intended for educational purposes only. You should not rely on this information as a replacement or substitution for professional medical advice, diagnosis, or treatment. If you have any concerns or questions about your health, you should always consult with a physician or other health-care professional. The use of cannabis while pregnant or breastfeeding may be harmful to both mother and child.
This test was developed, and its performance characteristics determined by Pathway Genomics Corporation (“Pathway”). Pathway’s laboratory is CLIA licensed and CAP accredited to perform high-complexity genetic testing. This test is to be used for health and wellness purposes and should not be used for medical diagnostic purposes. If you have any questions about this report or wish to speak with one of Pathway Genomics’ genetic counselors, please call (877) 505.7374. In addition, if you would like to obtain more information about markers or genotypes used in this test, then call customer service and Pathway can provide supplemental information.
RISKS AND LIMITATIONS
Risk of Laboratory Technical Problems or Laboratory Error
Pathway’s laboratory has standard and effective procedures in place to protect against technical and operational problems. However, such problems may still occur. Pathway’s laboratory receives samples collected by customers. Problems in shipping to the laboratory or sample handling can occur, including but not limited to damage to the specimen or related paperwork, mislabeling, and loss or delay of receipt of the specimen. Laboratory problems can occur that might lead to inability to obtain results. Examples include, but are not limited to, sample mislabeling, DNA contamination, un-interpretable results, and human and/or testing system errors. In such cases, Pathway’s laboratory may need to request a new sample. However, upon re-testing, results may still not be obtainable. There is a small chance that the laboratory could report inaccurate information. For example, the laboratory could report that a given genotype is present when in fact it is not. Any kind of laboratory error may lead to incorrect decisions regarding diet, nutrition and fitness recommendations.
The purpose of this test is to A) provide information on how an individual’s genes may affect his or her ability to metabolize cannabinoids, and B) offer recommendations to the individual based upon his or her genetics. The science underlying the interpretation of genetic variation, along with the utility of DNA testing continues to evolve; although great strides have been made, additional advancements will undoubtably occur. Both the acquisition of data and the interpretation of genetic test results are dependent upon scientific information and technology available at the time of testing; often, after a test has been performed, new developments can bring about changes in how previous test results should be interpreted. For example, any genetic test is limited by the variants under investigation; the interpretation and importance of some variants can change over time as additional data are gathered. On the other hand, some variants that are associated with a condition/trait or cannabinoid response may not be known at the time of testing; consequently, such variants cannot be included in a report. Many of the conditions described in this report are dependent on genetic factors as well as non-genetic variables such as age, personal health, family health history, exercise, diet, and ethnicity. Consequently, even though a person may possess genetic risk factors for a particular condition or cannabinoid response, he or she may never actually manifest said trait. If a customer’s ethnicity is not disclosed on the test requisition form, the ethnicity field in the report will read as ‘Ethnicity:Not Reported’.
This test and all its contents are Patent Pending by the United States Patent Office (USPTO #62/767,237).
1. U.S. Supreme Court. Gonzalez v. Raich, 545 U.S. 1. (2005).